Brainsway Begins Clinical Evaluation of New Deep TMS 360° Technology
Ticker: BRSYF · Form: 6-K · Filed: Jan 10, 2024 · CIK: 1505065
| Field | Detail |
|---|---|
| Company | Brainsway Ltd. (BRSYF) |
| Form Type | 6-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: clinical-trial, new-product, medical-device, press-release
TL;DR
**Brainsway is testing new tech, could be a big deal for future growth.**
AI Summary
On January 10, 2024, Brainsway Ltd. announced the initiation of a clinical evaluation for its new Rotational Field “Deep TMS 360°” Technology. This 6-K filing indicates that the company issued a press release (Exhibit 99.1) detailing this development. This matters to investors because successful clinical evaluation could lead to new product offerings and expanded market opportunities for Brainsway, potentially boosting its stock value.
Why It Matters
This filing signals Brainsway's progress in developing new medical technology, which could expand its product pipeline and future revenue streams if successful.
Risk Assessment
Risk Level: medium — While the initiation of clinical evaluation is positive, the success and market adoption of new medical technology are inherently uncertain, posing a medium risk.
Analyst Insight
Investors should monitor future announcements from Brainsway regarding the progress and results of the clinical evaluation for the Deep TMS 360° Technology, as positive outcomes could significantly impact the stock.
Key Players & Entities
- Brainsway Ltd. (company) — the registrant filing the 6-K
- Rotational Field “Deep TMS 360°” Technology (product) — the new technology undergoing clinical evaluation
- January 10, 2024 (date) — date of the press release and 6-K filing
Forward-Looking Statements
- Brainsway will provide updates on the clinical evaluation of its Deep TMS 360° Technology within the next 6-12 months. (Brainsway Ltd.) — medium confidence, target: 2025-01-10
FAQ
What is the primary purpose of this 6-K filing by Brainsway Ltd.?
The primary purpose of this 6-K filing is to report that Brainsway Ltd. issued a press release on January 10, 2024, announcing the initiation of a clinical evaluation for its Rotational Field “Deep TMS 360°” Technology.
What specific technology is Brainsway Ltd. evaluating, as mentioned in the filing?
Brainsway Ltd. is evaluating its Rotational Field “Deep TMS 360°” Technology, as stated in Exhibit 99.1 of the filing.
When was the press release regarding this clinical evaluation issued?
The press release (Exhibit 99.1) was issued on January 10, 2024, the same date as the 6-K filing.
Into which previous registration statements is this Form 6-K incorporated by reference?
This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed on April 22, 2019 (Registration No. 333-230979) and the Company's Registration Statement on Form F-3 filed on September 17, 2021 (Registration No. 333-259610).
What is Brainsway Ltd.'s Commission File Number?
Brainsway Ltd.'s Commission File Number is 001-35165, as indicated on the Form 6-K.
Filing Stats: 208 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-01-10 07:30:07
Filing Documents
- f6k_010924.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-000171.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRAINSWAY LTD. (Registrant) Date: January 10, 2024 /s/ Hadar Levy Hadar Levy Chief Executive Officer